Technology
Health
Biotechnology

Akebia Therapeutics

$3.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.13 (-3.21%) Today
$0.00 (0.00%) As of 7:46 PM EDT after-hours

Why Robinhood?

You can buy or sell AKBA and other stocks, options, ETFs, and crypto commission-free!

About AKBA

Akebia Therapeutics, Inc. Common Stock, also called Akebia Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. Read More The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Employees
325
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
474.35M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
758.84K
High Today
$4.07
Low Today
$3.83
Open Price
$4.03
Volume
1.01M
52 Week High
$10.74
52 Week Low
$3.83

Collections

Technology
Health
Biotechnology
Therapy
Biopharmaceutical
Pharmaceutical
2014 IPO
US

AKBA News

Yahoo FinanceJun 20

When Can We Expect A Profit From Akebia Therapeutics, Inc.?

285

AKBA Earnings

-$0.76
-$0.42
-$0.09
$0.25
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market

Popular Stocks

More AKBA News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.